33 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Novartis (Switzerland)CH3 papers
- Roche (Switzerland)CH3 papers
- Universitätsmedizin GöttingenDE3 papers
- University of FreiburgDE3 papers
- Bayer (Germany)DE2 papers
- Boehringer Ingelheim (Germany)DE2 papers
- Bristol-Myers Squibb (Germany)DE2 papers
- Helmholtz MunichDE2 papers
- Janssen (Germany)DE2 papers
- Merck KGaA, Darmstadt (Germany)DE2 papers
- University of GöttingenDE2 papers
- AstraZeneca (Sweden)SE1 paper
Showing 2020Show all
2 papers · 1 filter
stat.AP2020★ 28 cited
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- estimation of adverse event risks
Regina Stegherr, Claudia Schmoor, Jan Beyersmann +12
The SAVVY project aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up tim…
stat.AP2020★ 4 cited
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…